

Form PTO-1449 (modified)

Atty. Docket No.
12740.0232.NPUS01Serial No.
09/990,578

List of Patents and Publications for Applicant's

Applicant
Wallace L. McKeehan and Yongde Luo

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Filing Date:
November 21, 2001Group: JAN 07 2003
1623

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art
TECH CENTER 1600/2900

See Page 1

See Page 1

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
MCH	A10	5,707,632	01/13/98	Williams et al.	424	198.1	06/02/95
	A12	5,795,875	08/18/98	Holme et al.	514	56	01/09/97
	A11	5,801,063	09/01/98	Grandics et al.	436	518	05/09/95
	A13						
	A14						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
MCH	B2	WO 01/34641 A2	05/17/01	PCT			
	B3						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
MCH	C55	S. Uhlrich, O. Lagente, J. Choay, Y. Courtois and M. Lenfant; "Structure Activity Relationship in Heparin: Stimulation of Non-Vascular Cells by a Synthetic Heparin Pentasaccharide in Cooperation with Human Acidic Fibroblast Growth Factors"; September 16, 1986, Biochemical and Biophysical Research Communications, Vol. 139, No. 2; pages 728-732.
MCH	C56	Pauline Wong and Wilson H. Burgess; "FGF2-Heparin Co-crystal Complex-assisted Design of Mutants FGF1 and FGF7 with Predictable Heparin Affinities"; July 17, 1998; The Journal of Biological Chemistry, Vol. 273, No. 29, pp. 18617-18622.
MCH	C57	Hyae Gyeong Cheon; "Effect of Heparin on the High Affinity KGF and aFGF Binding to the Chimeric KGFR-HFc"; May 31, 1996; J. Biochem. Mol. Biol., Vol. 29, No. 3, pp. 205-209.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
12740.0232.NPUS01Serial No.
09/990,578

List of Patents and Publications for Applicant's

Applicant
Wallace L. McKeehan and Yongde Luo

RECEIVED

JAN 07 2003

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
November 21, 2001Group:
1623

TECH CENTER 1600/2900

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
M.C.H.	C58	Sheng Ye, Yongde Luo, Weiqin Lu, Richard B. Jones, robert J.Linhardt, Ishan Capila, Toshihiko Toida, Mikio Kan, Huguette Pellitier and Wallace L. McKeehan; "Structural Basis for Interaction of FGF-1, FGF-2 and FGF-7 with Different Heparan Sulfate Motifs"; November 6, 2001, Biochemistry 2001, 40, pages 14429-14439.
	C59	

EXAMINER:

DATE CONSIDERED:

12/8/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)


 Atty. Docket No.
12740.0232.NPUS00
(TAMK:232/REC)

 Serial No.
09/990,578

List of Patents and Publications for Applicant's

 Applicant
Wallace McKeehan and Yongde Luo

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

 Filing Date:
November 21, 2001

 Group:
1623

 U.S. Patent Documents
See Page 1

 Foreign Patent Documents
See Page 1

 Other Art
See Page 2

 RECEIVED
JUL 1 2002
TECH CENTER 1600/2800

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
M.C.H.	A1	5,965,530	10/12/99	Pierce et al.			
	A2	6,183,784	2/6/01	Read et al.			
	A3	5,843,883,	12/1/98	Gospodarowicz et al.			
	A4	5,034,520	7/23/91	Lormeau et al.			
	A5	5,807,982	9/15/98	McCaffrey et al.			
	A6	6,074,848	6/13/00	Gospodarowicz et al.			
	A7	5,655,870	9/9/1997	Rubin et al.			
	A8	5,891,655	4/6/1999	Ornitz			
M.C.H.	A9	6,127,347	10/3/2000	Chaudry et al.			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 98/16642	4/23/1998	WIPO	—	—	
	B2				—	—	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
M.C.H.	C1	Cook N. et al.; "Platelet Factor 4 Efficiently Reverses Heparin Anticoagulation in the Rat Without Adverse Effects of Heparin-Protamine Complexes" (1992) Circulation 85:1102-1109.
M.C.H.	C2	DiGabriele, A. D., et al.; "Structure of a Heparin-linked Biologically Active Dimer of Fibroblast Growth Factor" (1998) Nature 393, 812-817.




RECEIVED

Other Art (Including Author, Title, Date Pertinent Pages, Etc.) 1 2002

TECH CENTER 1600/2900

Exam. Init.	Ref. Des.	Citation
M.C.H.	C3	Faham, S., et al.; "Diversity Does Make a Difference: Fibroblast Growth Factor-Heparin Interactions" (1998) Curr. Opin. Struct. Biol. 8, 578-586.
	C4	Guimond, S., et al.; "Activating and Inhibitory Heparin Sequences for FGF-2 (Basic FGF)" (1993) J. Biol. Chem. 268, 23906-23914.
	C5	Guimond, S. E., and Turnbull, J. E.; "Fibroblast Growth Factor Receptor Signalling is Dictated By Specific Heparan Sulphate Saccharides" (1999) Curr. Biol. 9, 1343-1346.
	C6	Herr, A. B., et al.; "Heparin-Induced Self-Association of Fibroblast Growth Factor-2" (1997) J. Biol. Chem. 272, 16382-16389.
	C7	Ishihara, M., et al.; "Importance of 2-O-Sulfate Groups of Uronate Residues in Heparin for Activation of FGF-1 and FGF-2" (1997) J. Biochem. (Tokyo) 121, 345-349.
	C8	Jang, J. H., et al.; "Heparan Sulfate is Required for Interaction and Activation of the Epithelial Cell Fibroblast Growth Factor Receptor-2IIIb with Stromal-Derived Fibroblast Growth Factor-7" (1997) In Vitro Cell Dev. Biol. Anim., 33, 819-24.
	C9	Edmunds, T. et al.; "Transgenically Produced Human Antithrombin: Structural and Functional Comparison to Human Plasma-Derived Antithrombin" (1998) Blood, 91, 4561-4571.
	C10	Kan, M., et al.; "Specificity for Fibroblast Growth Factors Determined by Heparan Sulfate in a Binary Complex with the Receptor Kinase" (1999) J. Biol. Chem. 274, 15947-15952.
	C11	Kan, M., et al.; "An Essential Heparin-Binding Domain in the Fibroblast Growth Factor Receptor Kinase" (1993) Science 259, 1918-1921.
	C12	Kan, M. et al.; "Divalent Cations and Heparin/Heparan Sulfate Cooperate to Control Assembly and Activity of the Fibroblast Growth Factor Receptor Complex" (1996) J. Biol. Chem. 271, 26143-26148.
	C13	Kato, M. et al.; "Physiological Degradation Converts the Soluble Syndecan-1 Ectomdomain from an Inhibitor to a Potent Activator of FGF-2" (1998) Nat. Med. 4, 691-697.
	C14	Kim, P. J., et al.; "Colocalization of Heparin and Receptor Binding Sites on Keratinocyte Growth Factor" (1998) Biochemistry 37, 8853-8862.
	C15	Lindahl, U., et al.; "Regulated Diversity of Heparan Sulfate" (1998) J. Biol. Chem. 273, 24979-24982.
	C16	Lookene, A., et al.; "Interaction of Lipoproteins with Heparan Sulfate Proteoglycans and with Lipoprotein lipase. Studies by Surface Plasmon Resonance Technique" (1997) Biochemistry 36, 5267-5275.
	C17	Lu, W., et al.; "Fibroblast Growth Factor-10" (1999) [published erratum appears in J. Biol. Chem. (1999) 274, 28058] J. Biol. Chem. 274, 12827-12834.
M.C.H.	C18	Luo, Y., et al.; "Molecular Modeling and Deletion Mutagenesis Implicate the Nuclear Translocation Sequence in Structural Integrity of Fibroblast Growth Factor-1" (1996) J. Biol. Chem. 271, 26876-26883.




RECEIVED

JUL 1 2002

Other Art (Including Author, Title, Date Pertinent Pages) **GEN CENTER 1600/2900**

Exam. Init.	Ref. Des.	Citation
M.C.H.	C19 ✓	Luo, Y., et al.; "The Glycine Box: A Determinant of Specificity for Fibroblast Growth Factor" (1998) <i>Biochemistry</i> 37 , 16506-16515.
	C20 ✓	McKeehan, W. L., et al.; "The Heparan Sulfate-Fibroblast Growth Factor Family: Diversity of Structure and Function" (1998) <i>Prog. Nucleic Acid Res. Mol. Biol.</i> 59 , 135-176.
	C21 ✓	McKeehan, W. L., et al.; "Requirement for Anticoagulant Heparan Sulfate in the Fibroblast Growth Factor Receptor Complex" (1999) <i>J. Biol. Chem.</i> 274 , 21511-21514.
	C22 ✓	Mikhailov, D., et al.; "NMR Solution Conformation of heparin-Derived Hexasaccharide" (1997) <i>Biochem. J.</i> 328 , 51-61.
	C23 ✓	Moy, F. J., et al.; "Properly Oriented Heparin-Decasaccharide-Induced Dimers are the Biologically Active Form of basic Fibroblast Growth Factor" (1997) <i>Biochemistry</i> 36 , 4782-4791.
	C24 ✓	Ornitz, D. M., et al.; "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Trisaccharides" (1995) <i>Science</i> 268 , 432-436.
	C25 ✓	Ornitz, D. M.; "FGFs, Heparan Sulfate and FGFRs: Complex Interactions Essential for Development" (2000) <i>Bioessays</i> 22 , 108-112.
	C26 ✓	Pellegrini, L. et al.; "Crystal Structure of Fibroblast Growth Factor Receptor Ectodomain Bound to Ligand and Heparin" (2000) <i>Nature</i> , 407 , 1029-1034.
	C27 ✓	Rezaie, A. R., and Olson, S. T.; "Calcium Enhances Heparin Catalysis of the Antithrombin-Factor Xa Reaction by Promoting the Assembly of an Intermediate Heparin - Antithrombin - Factor Xa Bridging Complex. Demonstration by Rapid Kinetics Studies" (2000) <i>Biochemistry</i> 39 , 12083-12090.
	C28 ✓	Ron, D. et al.; "Expression of Biologically Active Recombinant Keratinocyte Growth Factor" (1993) <i>J. Biol. Chem.</i> 268 , 2984-2988.
	C29 ✓	Rosenberg, R. D., et al.; "Perspectives Series: Cell Adhesion in Vascular Biology; Heparan Sulfate Proteoglycans of the Cardiovascular System" (1997) <i>J. Clin. Invest.</i> 99 , 2062-2070.
	C30 ✓	Schlessinger, J. et al.; "Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin FGRF Binding and Dimerization" (2000) <i>Mol. Cell.</i> 6 , 743-750.
	C31 ✓	Shriver, Z., et al.; "Sequencing of 3-O Sulfate Containing Heparin Decasaccharides with a Partial Antithrombin III Binding Site" (2000) <i>Proc. Natl. Acad. Sci. USA</i> , 97 , 10359-10364.
	C32 ✓	Shriver, Z. et al.; "Cleavage of the Antithrombin III binding site in Heparin by Heparinases and its Implication in the Generation of Low Molecular Weight Heparin" (2000) <i>Proc. Natl. Acad. Sci. USA</i> , 97 , 10365-10370.
M.C.H.	C33 ✓	Toida, T., et al.; "Enzymatic Preparation of Heparin Oligosaccharides Containing Antithrombin III Binding Sites" (1996) <i>J. Biol. Chem.</i> 271 , 32040-32047.



RECEIVED

Other Art (Including Author, Title, Date Pertinent Pages, Etc.) L 1 2002

TECH CENTER 1600/2900

Exam. Init.	Ref. Des.	Citation
M-C H	C34 ✓	Uematsu F, et al.; "Ligand Binding Properties of Binary Complexes of Heparin and Immunoglobulin-like Modules of FGF Receptor 2" (2000) Biochem. Biophys. Res. Commun. 272 , 830-836.
	C35 ✓	Vlodavsky, I., et al.; "Involvement of Heparan Sulfate and Related Molecules in Sequenstration and Growth promoting Activity of Fibroblast Growth Factor" (1996) Cancer Metastasis Rev. 15 , 177-186.
	C36 ✓	Waksman, G., and Herr, A. B.; "New Insights into Heparin-Induced FGF Oligomerization" (1998) Nat. Struct. Biol. 5 , 527-530.
	C37 ✓	Wang, F., et al.; "Alternately Spliced NH ₂ - Terminal Immunoglobulin-like Loop I in the Ectodomain of the Fibroblast Growth Factor (FGF) Receptor 1 Lowers Affinity for Both Heparin and FGF-1" (1995) J. Biol. Chem. 270 , 10222-10230.
	C38 ✓	Wang, F., et al.; "Common and Specific Determinants for Fibroblast Growth Factors in the Ectodomain of the Receptor Kinase Complex" (1999) Biochemistry 38 , 160-171.
	C39 ✓	Ye, S., et al.; "Exon Switching and Activation of Stromal and Embryonic Fibroblast Growth Factor (FGF)-FGF Receptor Genes in Prostate Epithelial Cells Accompany Stromal Independence and Malignancy" (2001) Biochemistry 40 , 14429-14439.
	C40 ✓	J. Choay, et al.; "Structure-Activity Relationship in Heparin: A Synthetic Pentasaccharide with High Affinity for Antithrobin III and Eliciting High Anti-Factor Xa Activity" (1983) Biochemical and Biophysical Research Communications, Vol. 116, No. 2, 492-499
	C41 ✓	Duraikkannu Loganathan, et al.; "Structural Variation in the Antithrombin III Binding Site Region and Its Occurrence in Heparin from Different Sources" (1990) Biochemistry 29 , 4362-4368.
	C42 ✓	Alireza R. Rezaie, "Heparin-Binding Exosite of Factor Xa" (2000) TCM Vol. 10, No. 8, 333-338.
	C43 ✓	Tahir Ahmed, et al., "Inhibition of Allergic Late Airway Responses by Inhaled Heparin-Derived Oligosaccharides" (2000) J. Appl. Physiol 88 , 1721-1729.
	C44 ✓	E. Sache, et al.; "Partially N-Desulfated Heparin as a Non-Anticoagulant Heparin: Some Physico-Chemical and Biological Properties" (1989) Thrombosis Research 55 , Vol. 55, No. 2, 247-258.
	C45 ✓	Guangli Yu, et al.; "Heparinase I Acts on a Synthetic Heparin Pentasaccharide Corresponding to the Antithrombin III Binding Site" (2000) Thrombosis Research 100 , 549-556.
M-C H	C46 ✓	Allison Fryer, et al.; "Selective O-Desulfation Produces Nonanticoagulant Heparin that Retains Pharmacological Activity in the Lung ^{1,2} " (1997) The Journal Of Pharmacology and Experimental Therapeutics, Vol. 282, No. 1, 282 , 208-219.



RECEIVED

JUL 1 2002

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
M.C.H.	C47	Peter C. Kouretas, et al.; "Non-Anticoagulant Heparin Increases Endothelial Nitric Oxide Synthase Activity: Role of Inhibitory Guanine Nucleotide Proteins" (1998) J Mol Cell Cardiol 30, 2669-2682.
	C48	Shinobu Mochizuki, et al.; "Expression and Characterization of Recombinant Human Antithrombin III in Pichia Pastoris" (2001) Protein Expression and Purification 23, 55-65.
	C49	Alexander N. Plotnikow, et al.; "Crystal Structure of Fibroblast Growth Factor 9 Reveals Regions Implicated in Dimerization and Autoinhibition" (2001) The Journal of Biological Chemistry, Vol. 276, No. 6, 4322-4329.
	C50	Paola Bellosta, et al.; "Identification of Receptor and Heparin Binding Sites in Fibroblast Growth Factor 4 by Structure-Based Mutagenesis" (2001) Molecular and Cellular Biology, 5946-5957.
	C51	David A. Pye, et al.; "Regulation of FGF-1 Mitogenic Activity by Heparan Sulfate Oligosaccharides is Dependent on Specific Structural Features: Differential Requirements for the Modulation of FGF-1 and FGF-2" (2000) Glycobiology, Vol. 10, No. 11, 1183-1192.
	C52	J.N. Shanberge, et al.; "Interrelationship of Protamine and Platelet Factor 4 in the Neutralization of Heparin" (1987) Thrombosis Research 46, 89-100.
	C53	Man-Chiu Poon, et al.; "Platelet Factor Four and Protamine Sulfate Neutralization of Heparin Fractionated According to Anionic Charge Density" (1982) Thromb Haemostas (Stuttgart) 47 (2), 162-165.
M.C.H.	C54	Thierry Burnouf, et al.; "Affinity Chromatography in the Industrial Purification of Plasma Proteins for Therapeutic Use" (2001) J. Biochem. Biophys. Methods 49, 575-586.

12/8/03